Skip to content

Author

Fangjie Liu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Jul 2026

Abstract A015: JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor

JAB-BX600 exhibits potent anti-tumor activity in KRAS G12D-mutant tumor models and a favorable preclinical safety profile, which support further clinical development of JAB-BX600 as a promising therapeutic strategy for KRAS G12D-driven cancers, particularly CRC and PDAC.

Peng Wang, Fangjie Liu, Xiaoyu Liu et al. · 0 citations
Jul 2026

Abstract PR005: JAB-BX600, a first-in-class EGFR-directed antiboEdy drug conjugate delivering a novel KRAS G12D inhibitor

In contrast to non-small cell lung cancer and pancreatic cancer, KRAS inhibitors exhibited limited single agent activities in colorectal cancer (CRC), largely owing to EGFR-mediated adaptive MAPK pathway reactivation and intratumor heterogeneity. JAB-BX600, a humanized, EGFR-targeted antibody-drug conjugate (ADC)...

Peng Wang, Fangjie Liu, Xiaoyu Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.